Synergy Pharmaceuticals – U.S. Trustee Joins Chorus of Objections to Equity Committee’s Retention of Houlihan Lokey and Unreasonable Fees

March 15, 2019 – The U.S. Trustee assigned to Synergy Pharmaceuticals cases objected to the retention of Houlihan Lokey Capital, Inc. (“Houlihan”) as financial advisor and investment banker to the Debtors’ Official Committee of Equity Security Holders (the “Equity Committee”) [Docket No. 555], citing unreasonableness of Houlihan's fees in the liquidation context and the lack…